id: NEW:adjuvant_radiotherapy_access_to_NEW:ipsilateral_breast_tumor_recurrence
name: Access to Adjuvant Radiotherapy After Breast-Conserving Surgery â†’ Ipsilateral Breast Tumor Recurrence
from_node:
  node_id: NEW:adjuvant_radiotherapy_access
  node_name: Access to Adjuvant Radiotherapy After Breast-Conserving Surgery
to_node:
  node_id: NEW:ipsilateral_breast_tumor_recurrence
  node_name: Ipsilateral Breast Tumor Recurrence
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: After breast-conserving surgery, microscopic residual disease may remain in breast tissue'
- 'Step 2: Adjuvant radiotherapy delivers targeted ionizing radiation to remaining breast tissue'
- 'Step 3: Radiation induces DNA damage and apoptosis in residual abnormal cells'
- 'Step 4: Elimination of microscopic disease reduces risk of both invasive and non-invasive ipsilateral
  recurrence'
evidence:
  quality_rating: A
  n_studies: 33
  primary_citation: 'Qian Chen et al. 2024. "Outcomes from low-risk ductal carcinoma in situ: a systematic
    review and meta-analysis." https://doi.org/10.1007/s10549-024-07473-w'
  supporting_citations:
  - Studies within meta-analysis comparing BCS alone vs BCS with radiotherapy
  - Additional citations require full-text access for specific trial identifiers
  - Evidence base includes observational studies primarily
  doi: 10.1007/s10549-024-07473-w
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: In patients who underwent breast-conserving surgery for low-risk DCIS, additional radiotherapy
  significantly reduced the risk of ipsilateral breast tumor events (IBTE). However, radiotherapy did
  not reduce the risk of contralateral breast cancer (CBC), suggesting its effect is localized to the
  treated breast.
quantitative_effects:
  sample_size: 47696
structural_competency:
  equity_implications: Access to adjuvant radiotherapy depends on healthcare infrastructure including
    radiation oncology facilities, which are often concentrated in urban centers. Rural populations and
    those without comprehensive cancer centers may face barriers to receiving guideline-concordant treatment.
    Transportation burden, treatment duration (typically 3-6 weeks of daily treatments), and insurance
    coverage for radiation therapy represent structural determinants of whether patients receive this
    survival-improving intervention.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.889453'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
